Cimetidine: A Safe Treatment Option for Cutaneous Warts in Pediatric Heart Transplant Recipients
Abstract
1. Introduction
2. Methods
3. Results
4. Discussion
Study Limitations
5. Conclusions
Acknowledgments
Author Contributions
Conflict of Interest
References
- Bruggink, S.C.; de Koning, M.N.; Gusseklo, J.; Egberts, P.F.; Ter Schegget, J.; Feltkamp, M.C.; Bavinck, J.N.; Quint, W.G.; Assendelft, W.J.; Eekhof, J.A. Cutaneous warts-associated HPV types: Prevalence and relation with patient characteristics. J. Clin. Virol. 2012, 55, 250–255. [Google Scholar] [CrossRef] [PubMed]
- Kilkenny, M.; Marks, R. The descriptive epidemiology of warts in the community. Aust. J. Dermatol. 1996, 37, 80–86. [Google Scholar] [CrossRef]
- Fortina, A.B.; Piaserico, S.; Alaibac, M.; Caforio, A.L.P.; Brandolisio, L.; Zacchello, G.; Zanon, G.F.; Zancan, L.; Peserico, A. Skin disorders in patients transplanted in childhood. Transpl. Int. 2005, 18, 360–365. [Google Scholar] [CrossRef] [PubMed]
- Dyall-Smith, D.; Trowell, H.; Dyall-Smith, M.L. Benign human papillomavirus infection in renal transplant recipients. Int. J. Dermatol. 1991, 30, 785–789. [Google Scholar] [CrossRef] [PubMed]
- Viac, J.; Thivolet, J.; Chardonnet, Y. Specific immunity in patients suffering from recurring warts before and after repetitive intradermal tests with human papilloma virus. Br. J. Dermatol. 1977, 97, 365–370. [Google Scholar] [CrossRef] [PubMed]
- Beutner, K.R.; Reitano, M.V.; Richwald, G.A.; Wiley, D.J. The AMA Expert Panel on External Genital Warts. External Genital Warts: Report of the American Medical Association Consensus Conference. Clin. Infect Dis. 1998, 27, 796–806. [Google Scholar] [CrossRef] [PubMed]
- Chern, E.; Cheng, Y.W. Treatment of recalcitrant periungual warts with cimetidine in pediatrics. J. Dermatol. Treat. 2010, 21, 314–316. [Google Scholar] [CrossRef] [PubMed]
- Orlow, S.J.; Paller, A. Cimetidine therapy for multiple viral warts in children. J. Am. Acad. Dermatol. 1993, 28, 794–796. [Google Scholar] [CrossRef]
- Gooptu, C.; Higgins, C.R.; James, M.P. Treatment of viral warts with cimetidine: An open-label study. Clin. Exp. Dermatol. 2000, 25, 183–185. [Google Scholar] [CrossRef] [PubMed]
- Fischer, G.; Rogers, M. Cimetidine therapy for warts in children. J. Am. Acad. Dermatol. 1997, 37, 289–290. [Google Scholar] [CrossRef]
- Bauman, C.; Francis, J.S.; Vanderhooft, S.; Sybert, V. Cimetidine therapy for multiple viral warts in children. J. Am. Acad. Dermatol. 1996, 35, 271–272. [Google Scholar] [CrossRef]
- Rogers, C.J.; Gibney, M.D.; Siegfried, E.C.; Harrison, B.R.; Glaser, D.A. Cimetidine therapy for recalcitrant warts in adults: Is it any better than placebo? J. Am. Acad. Dermatol. 1999, 41, 123–127. [Google Scholar] [CrossRef]
- Yilmaz, E.; Alpsoy, E.; Basaran, E. Cimetidine therapy for warts: A placebo-controlled, double blind study. J. Am. Acad. Dermatol. 1996, 34, 1005–1007. [Google Scholar] [CrossRef]
- Scheinfeld, N. Treatment of molluscum contagiosum: A brief review and discussion of a case successfully treated with adapalene. Dermatol. Online J. 2007, 13, 15. [Google Scholar] [PubMed]
- Lipke, M.M. An Armamentarium of Wart Treatments. Clin. Med. Res. 2006, 4, 273–293. [Google Scholar] [CrossRef] [PubMed]
- Mitsuishi, T.; Iida, K.; Kawana, S. Cimetidine treatment for viral warts enhances IL-2 and IFN-γ expression but not IL-18 expression in lesional skin. Eur. J. Dermatol. 2003, 13, 445–448. [Google Scholar] [PubMed]
- Alsutany, H.A.; Alshibly, I.K. Immunomodulating activity of cimetidine in Iraqi children and adolescents with common warts. Med. J. Babylon 2014, 11, 547–556. [Google Scholar]
- Jafarzadeh, A.; Nemati, M.; Rezayati, M.T.; Ebrahimi, M.; Hassan, Z.M. Cimetidine enhances delayed-type hypersensitivity responses and serum interleukin (IL)-2, -10, -12, and IL-17 levels after burn injury in an animal model. J. Immunotoxicol. 2013, 10, 201–209. [Google Scholar] [CrossRef] [PubMed][Green Version]
- Elenkov, I.J.; Webster, E.; Papanicolaou, D.A.; Fleisher, T.A.; Chrousos, G.P.; Wilder, R.L. Histamine potently suppresses human IL-12 and stimulates IL-10 production via H2 receptors. J. Immunol. 1998, 161, 2586–2593. [Google Scholar] [PubMed]
- Gifford, R.R.; Tilberg, A.F. Histamine type-2 receptor antagonist immune modulation. II. Cimetidine and ranitidine increase interleukin-2 production. Surgery 1987, 102, 242–247. [Google Scholar] [PubMed]
- Karaman, G.; Sendur, N.; Sevk, E. Ranitidine therapy for recalcitrant warts in adults: A preliminary study. J. Eur. Acad. Dermatol. Venereol. 2001, 15, 495–496. [Google Scholar] [CrossRef] [PubMed]
- Gormley, R.H.; Kovarik, C.L. Human papillomavirus-related genital disease in the immunocompromised host: Part II. J. Am. Acad. Dermatol. 2012, 66, e1–e17. [Google Scholar] [CrossRef] [PubMed]
- Cimetidine (Tagamet)®: Product Information from GlaxoSmithKline Australia Pvt Ltd., Most Recent Amendment 12 March 2008. Issue No. 16(M). Available online: https://pdfs.semanticscholar.org/19d3/c2e3873f5bded43a1e7c6e0abc69c7d63a48.pdf (accessed on 2 March 2018).
- Deepinder, F.; Braunstein, G.D. Drug-induced gynecomastia: An evidence-based review. Expert Opin. Drug Saf. 2012, 11, 779–795. [Google Scholar] [CrossRef] [PubMed]
Patient | Age in years. | Sex | Yrs. after HT | Immunosuppression Rx | Types of Warts | Rx with Cimeti-Dine in Months | Adverse Effects | Outcome of Warts after 6 Months | Outcome of Warts at 1 year. Follow-up |
---|---|---|---|---|---|---|---|---|---|
1 | 18 | F | 1 | T + MMF | Verruca Vulgaris (Figure 1) | 5 | None | Resolved | No-recurrence |
2 | 9 | F | 2 | T + MMF | Verruca plantaris (Figure 2) | 6 | None | Resolved | Recurrence of warts, resolved after 3 months re-treatment |
3 | 15 | F | 3 | T + MMF | Verruca vulgaris | 5 | Pruritus | Resolved | No-recurrence |
4 | 16 | M | 6 | T + MMF | Verruca vulgaris | 6 | Gynecomastia | Resolved | No-recurrence |
5 | 13 | F | 3 | T + MMF | Verruca vulgaris | 6 | None | Resolved | No-recurrence |
6 | 7 | F | 4 | T + MMF | Verruca vulgaris | 6 | None | Resolved | No-recurrence |
7 | 7 | F | 5 | T + AZ | Verruca Vulgaris & Condyloma accuminata (Figure 3) | 6 | None | No effect | No effect |
8 | 10 | M | 9 | T + MMF | Verruca vulgaris | 3 | None | Recurred at end of 3 months Rx | Resolved after 6 months re-treatment with cimetidine |
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Das, B.B.; Anton, K.; Soares, N.; Riojas, S.; Mcdermott, J.; Knox, L.; Daneman, S.; Puente, B.N. Cimetidine: A Safe Treatment Option for Cutaneous Warts in Pediatric Heart Transplant Recipients. Med. Sci. 2018, 6, 30. https://doi.org/10.3390/medsci6020030
Das BB, Anton K, Soares N, Riojas S, Mcdermott J, Knox L, Daneman S, Puente BN. Cimetidine: A Safe Treatment Option for Cutaneous Warts in Pediatric Heart Transplant Recipients. Medical Sciences. 2018; 6(2):30. https://doi.org/10.3390/medsci6020030
Chicago/Turabian StyleDas, Bibhuti B, Kristin Anton, Nelia Soares, Susan Riojas, Jodi Mcdermott, Leah Knox, Susan Daneman, and Bao N Puente. 2018. "Cimetidine: A Safe Treatment Option for Cutaneous Warts in Pediatric Heart Transplant Recipients" Medical Sciences 6, no. 2: 30. https://doi.org/10.3390/medsci6020030
APA StyleDas, B. B., Anton, K., Soares, N., Riojas, S., Mcdermott, J., Knox, L., Daneman, S., & Puente, B. N. (2018). Cimetidine: A Safe Treatment Option for Cutaneous Warts in Pediatric Heart Transplant Recipients. Medical Sciences, 6(2), 30. https://doi.org/10.3390/medsci6020030